Q2 2026 saw strong Medicaid and Medicare duals performance, offsetting Marketplace losses and MAPD exit. Full-year EPS guidance was raised to at least $5.25, with 2027 EPS building blocks exceeding $10 per share and long-term targets reaffirmed.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.